NCT06942572: An ongoing trial by Splice Bio
This trial is ongoing. It must report results 3 years, 5 months from now.
Full data
| Full entry on ClinicalTrials.gov | NCT06942572 |
|---|---|
| Title | A Phase 1/2, First-in-Human, Open-label, Assessor-Masked, Randomized, Controlled, Dose Escalation/Expansion Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of a Subretinal Injection of SB-007 in Subjects With Stargardt Disease (STGD1) Caused by Bi-Allelic Autosomal Recessive Mutations in the ATP Binding Cassette Subfamily A Member 4 (ABCA4) Gene |
| Results Status | Ongoing |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | Feb. 11, 2025 |
| Completion date | Oct. 31, 2028 |
| Required reporting date | Oct. 31, 2029, midnight |
| Actual reporting date | None |
| Date last checked at ClinicalTrials.gov | May 29, 2026 |
| Days late | None |